MBOT logo

MICROBOT MEDICAL INC

MBOTNASDAQ
🏆 #4192 by market capUS Equity
$582.75▲ $10.66 (+1.83%)
Simulated price
🔔
Track MBOT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.8%
7d▲ 41824.5%
14d▲ 40228.7%
30d▲ 39408.5%
ytd▲ 29037.5%
1y▲ 18225.5%
🏦Market Cap
$84M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
-185.3%
Thin
💵FCF Margin
6933.4%
Strong
⚖️P/S Ratio
247.5x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$576.48 – $586.33
52-Week Range
$1.26 – $3.47
Volume
$2.00B
Avg Volume
$2.39B
Shares Outstanding
67.2M
Next Earnings
Oct 23, 2026

Fundamentals Snapshot

Annual Revenue
$339,269
Last Q Revenue
$241,000
P/E Ratio
—
P/S Ratio
247.5x
EPS (TTM)
$-0.26
Dividend Yield
—
Dilution (1yr)
+294.6%

Why Investors Own MBOT

  • ✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 42% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MBOT logo

MICROBOT MEDICAL INC

MBOT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▲ +26.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▲ +48.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
67.2M▲ +294.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$44K YoY
StockOtter · stockotter.space

About MICROBOT MEDICAL INC

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$618.38
▲ +6.1% Upside
High Target$686.72
Low Target$498.73
Based on 22 analysts

Latest News & Updates

🚀
CNBC·2h ago

MICROBOT MEDICAL INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift MBOT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

MICROBOT MEDICAL INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.